In the present study, expression of PPAR-α, -β/δ, -γ, and PGC-1α after combination therapy, may imply an amelioration of insulin resistance and improvement of mitochondrial function in skeletal muscle of obesity and diabetes. This evidence concerns the gene PPARGC1A and obesity due to melanocortin 4 receptor deficiency.